Date: 2013-11-04
Type of information: Grant
Company: MiRacle Consortium [InteRNA Technologies (The Netherlands), VU University Medical Center (The Netherlands), Quiet Therapeutics (Israel), Octoplus, subsidiary of Dr. Reddy’s Laboratories(The Netherlands) LPT (Germany) BioSpring (Germany)]
Investors: European Commission’s Seventh Framework Program (FP7)
Amount: € 1.2 Million
Funding type: grant
Planned used: MiRacle focuses on the development of a targeted therapeutic formulation for the treatment of head and neck cancer. The goal of MiRacle is the advancement of the safe, targeted delivery of therapeutic tumor-selective lethal miRNA formulation towards the clinic by combining two innovative technologies, i.e. application of therapeutic miRNAs using cancer cell-specific targeted drug delivery.
Others: * On November 4, 2013, InteRNA Technologies B.V., the Dutch biopharma company engaged in the development of microRNA (miRNA)-based therapeutics for oncology, and VU University Medical Center (VUmc) have announced they have been granted funding from the European Union’s FP7program “Research for the benefit of SMEs”. InteRNA and VUmc, who are leading this consortium, together with Quiet Therapeutics Ltd (Israel), a biopharma SME engaged in the development of a new class of highly selective targeted therapeutics for oncology and inflammation, have been granted around € 1.2 million, to develop the targeted delivery of novel tumor-selective lethal miRNAs for the treatment of head and neck cancer. The consortium further includes BioSpring (Germany), OctoPlus (the Netherlands) and the Laboratory of Pharmacology and Toxicology LPT (Germany).
Therapeutic area: Cancer - Oncology
